Notably, critical markers of apoptosis such as caspase-3 and BCL2 expression are reduced with nilotinib, consistent with volumetric magnetic resonance imaging (MRI) that show reduced atrophy of hippocampal volume in nilotinib-treated AD patients [33]. The gene discussed is BCL2; the disease is Alzheimer disease.